PHARMACOKINETICS OF CEFODIZIME IN ELDERLY PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT

被引:6
|
作者
VEYSSIER, P
DEVILLERS, A
DOMART, Y
FOURTILLAN, JB
BRYSKIER, A
PROCYK, T
机构
[1] CHU POITIERS,F-86021 POITIERS,FRANCE
[2] CTR HOSP V DUPOUY,ARGENTEUIL,FRANCE
关键词
D O I
10.1093/jac/26.suppl_C.77
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In young adults, the elimination half-life of cefodizime is 3.5—4 h. A pharmacokinetic study was performed in eight patients, aged 63 to 85 years, divided into two groups with the following creatinine clearances (group I: ≥ 50 ml/min and group II: < 30 ml/min). Cefodizime was administered as a 1.0-g iv bolus. In group I, pharmacokinetic parameters did not differ from those observed in young healthy volunteers in a previous study. In group II, the half-life was increased (3.42–7.41 h). There is a linear correlation between the creatinine clearance and total clearance. The daily dose given needs to be based not on the age of the patient but on the degree of renal impairment. In elderly patients with severe renal impairment, the daily dose should be reduced if the creatinine clearance falls below 30 ml/min. © 1990 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [31] Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment
    Saag, Kenneth G.
    Whelton, Andrew
    Becker, Michael A.
    MacDonald, Patricia
    Hunt, Barbara
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (08) : 2035 - 2043
  • [32] Effect of severe renal impairment on the pharmacokinetics of brigatinib
    Gupta, Neeraj
    Hanley, Michael J.
    Kerstein, David
    Tugnait, Meera
    Narasimhan, Narayana
    Marbury, Thomas C.
    Venkatakrishnan, Karthik
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1306 - 1314
  • [33] Influence of Severe Renal Impairment on the Pharmacokinetics of Clazosentan
    Bruderer, Shirin
    Sasu, Boris
    Tsvitbaum, Nahum
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03): : 413 - 421
  • [34] Effect of severe renal impairment on the pharmacokinetics of brigatinib
    Neeraj Gupta
    Michael J. Hanley
    David Kerstein
    Meera Tugnait
    Narayana Narasimhan
    Thomas C. Marbury
    Karthik Venkatakrishnan
    Investigational New Drugs, 2021, 39 : 1306 - 1314
  • [35] PHARMACOKINETICS OF BRIVARACETAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT
    Stockis, A.
    Jacobs, T.
    Leonard, M.
    Sargentini-Maier, M. L.
    EPILEPSIA, 2010, 51 : 122 - 123
  • [36] The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment
    De Wolf, AM
    Fragen, RJ
    Avram, MJ
    Fitzgerald, PC
    Rahimi-Danesh, F
    ANESTHESIA AND ANALGESIA, 2001, 93 (05): : 1205 - 1209
  • [37] PHARMACOKINETICS OF SUNITINIB IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END STAGE RENAL DISEASE ON HEMODIALYSIS
    Bello, C.
    Toh, M.
    Garrett, M.
    La Fargue, J.
    Ni, G.
    Khosravan, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 162 - 162
  • [38] Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment
    Christopher, Ronald J.
    Morgan, Michael E.
    Tang, Yong
    Anderson, Christen
    Sanchez, Matilde
    Shanahan, William
    CLINICAL THERAPEUTICS, 2017, 39 (04) : 837 - 848
  • [39] Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment
    Grasela, DM
    Christofalo, B
    Kollia, GD
    Duncan, G
    Noveck, R
    Manning, JA
    LaCreta, FP
    PHARMACOTHERAPY, 2000, 20 (06): : 87S - 94S
  • [40] Safety of Edoxaban 30 mg in Elderly Patients with Severe Renal Impairment
    Giovanni Fazio
    Ilaria Dentamaro
    Rosanna Gambacurta
    Pasquale Alcamo
    Paolo Colonna
    Clinical Drug Investigation, 2018, 38 : 1023 - 1030